In response [4]

Clinical Cancer Research

Volumn 12, Issue 20 PART 1, 2006, Pages 6206-6207

  Wardelmann, Eva ^a   Biermann, Katharina ^a   Merkelbach Bruse, Sabine ^a   Schildhaus, Hans Ulrich ^a   Thomas, Nadja ^a   Büttner, Reinhard ^a   Pietsch, Torsten ^a   Heinicke, Thomas ^a   Speidel, Nicola ^a   Pink, Daniel ^b   Reichardt, Peter ^b   Hohenberger, Peter ^c  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Section of Pathology   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; SUNITINIB;

CANCER GROWTH; CANCER SURVIVAL; EXON; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LETTER; MEDICAL SOCIETY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 33750684337     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1749     Document Type: Letter

References (3)

1. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-103.
2. Van Glabbeke M, Verweij J, Casali P, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Trials Group study. J Clin Oncol 2005;23:5795-804.
3. Raut C, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24:2325-31.